Indoleamine 2,3-dioxygenase 1 (IDO1), known as IDO, catabolizes tryptophan through kynurenine pathway, whose activity is correlated with impaired clinical outcome of colorectal cancer. Here we showed that 1-L-MT, a canonical IDO inhibitor, suppressed proliferation of human colorectal cancer cells through inducing mitotic death. Our results showed that inhibition of IDO decreased the transcription of CDC20, which resulted in G2/M cycle arrest of HCT-116 and HT-29. Furthermore, 1-L-MT induced mitochondria injuries and caused apoptotic cancer cells. Importantly, 1-L-MT protected mice from azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colon carcinogenesis, with reduced mortality, tumor number and size. What is more, IDO1-/-mice exhibited fewer tumor burdens and reduced proliferation in the neoplastic epithelium, while, 1-L-MT did not exhibit any further protective effects on IDO-/-mice, confirming the critical role of IDO and the protective effect of 1-L-MT-mediated IDO inhibition in CRC. Furthermore, 1-L-MT also alleviated CRC in Rag1-/-mice, demonstrating the modulatory effects of IDO independent of its role in modulating adaptive immunity. Taken together, our findings validated that the antiproliferation effect of 1-L-MT in vitro and the prevention of CRC in vivo were through IDO-induced cell cycle disaster of colon cancer cells. Our results identified 1-L-MT as a promising candidate for the chemoprevention of CRC.
involved in CRC progression, and correlated with poor clinical outcome. 6 What is more, it was reported that systemic administration of Salmonella inhibited tumor growth and extended the survival of mice bearing colon cancer via suppressing IDO activation. 7 Although IDO expression has been reported in human CRC, 8, 9 the function of IDO activity in this disease remains unclear. IDO participates in pathogenic inflammation and engenders immune tolerance to tumor antigens. 10 IDO degrades tryptophan and produces many toxic kynurenine (Kyn) metabolites, which mediate immune tolerance. 11 The function of IDO involves multiple effects on T lymphocytes, 12 including inhibiting activated T cells proliferation, inducing apoptosis of CD8
1
T cells, and promoting differentiation of CD4 1 T cells towards a regulatory phenotype. 13, 14 Nowadays, more attention has been focused on the effects of IDO independent of its role in adaptive immunity. It was demonstrated that blockade of IDO activity in cancer cells could reduce bcatenin activation and inhibit cell proliferation. 15 Knockdown of IDO decreased the formation of vasculogenic mimicry of lung cancer. 16 Silence of IDO in melanoma cells inhibited cancer cell proliferation and induced greater cell apoptosis. mTOR activity, inducing autophagy and increasing NAD 1 levels. 18, 19 In our study, we found that IDO inhibitors significantly induced mitotic death in HCT-116 and HT-29 colon cancer cells. Thus, apart from immune tolerance, IDO activation contributed pathologically to tumorigenesis of colon cancer.
IDO has been regarded as an attractive target for both prevention and treatment of many cancer. 1-MT is a canonical IDO inhibitor with low toxicity, which is well tolerated by cancer patients. Moreover, 1-MT, combined with several chemotherapeutic drugs, resulted in rapid eradication of established malignancies. 10, 20 What is more, Ogawa et al.
identified that 1-L-MT, an isomer of 1-MT, suppressed AOM-induced colonic preneoplastic lesions in rats. 21 1-L-MT, but not 1-D-MT exhibited greater effects on antiproliferation of colon cancer cells. 15 Consistently, AOM/DSSinduced sporadic colon cancer was prevented by 1-L-MT administration in our in vivo study. Hence, we assumed that 1-L-MT could potentially be used for chemoprevention against colitis-associated cancer.
In the present study, we validated that 1-L-MT inhibited proliferation of human colorectal cancer cells through inducing cell cycle arrest-mediated apoptosis. Importantly, supplementing the diet with 1-L-MT protected mice against AOM/ DSS-induced colon carcinogenesis independent of its role in adaptive immunity.
Material and Methods
Reagents 1-L-MT purchased from Sigma-Aldrich was dissolved in 0.1 M NaoH at 50 mM. INCB purchased from selleck was dissolved in DMSO 5 mM. Primary antibodies for IDO, CDC20, b-actin, Lamin A, and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Bioworld Technology, Inc. AhR antibody were purchased from Abclonal, Boston, MA. aTubulin, Mad2 and BubR1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Cleaved caspase 3, 8, 9, Bcl-2, phospho-histone H3, CDK1 (Tyr15), phospho-CDK1 (Thr161) and CDK1 antibodies were purchased from Cell Signaling Technology (Beverly, MA). Phorbol ELISA kits for Trp, Kyn and INF-g were purchased from Nanjing SenBeiJia Biological Technology Co., Ltd.
Cell culture
Human colon cancer cell lines (HCT116 and HT29) were obtained from Cell Bank of the Chinese Academic of Sciences (Shanghai, China) and cultured in RPMI 1640 medium supplemented with 10% FBS. Both cell lines were cultured under a humidified 5% (v/v) CO2 atmosphere at 378C. HCT116 and HT29 were authenticated with methods of short tandem repeat (STR).
Western blot assay
Total proteins were extracted by adding RIPA lysis buffer with 1 mM PMSF for 1 hr on the ice and centrifuging at 13,000 rpm for 30 min at 48C. Protein concentration in the supernatants was measured by BCA protein assay (Thermo). Then, equal amount of sample was run on 10% SDS PAGE. The proteins were transferred to polyvinylidene difluoride membranes (Millipore) using a semidry transfer system (Biorad). Proteins were detected using specific antibodies of IDO, BubR1, MAD2, p-Histone, CDC20, Cyclin B1, CDK, p-CDK Thr 161, p-CDK Try 15, tublin, PARP, MPM2 cleaved caspase 3,8,9, Bcl-2 and b-actin overnight at 48C. The membranes were then washed three times with PBST followed by HRP-conjugated secondary antibodies for 1 hr at 378C. All the antibodies were diluted in PBST containing 1% BSA. The signals were analyzed using the ECL chemiluminescence detection system (Tanon).
Plate colony-formation assay
Cells were seeded in six-well plates at 100 cells/well in RPMI-1640 culture medium with different stimulations. Plates were further incubated for a week until the colonies were large enough to be visualized. The colonies were pictured at 2003 magnification to detect colony size.
Colorimetric MTT assay
The cytotoxicity was measured by the modified MTT assay. Briefly, the logarithmic cells were plated into 96-well plates at a density of 4,000 to 5,000 cells/well in a final volume of 100 ll medium for 24 or 48 hr at 378C and then treated with different stimulations for indicated time. After 24 or 48 hr incubation, the absorbance (A) was measured at 570 nm by the Universal Microplate Reader (ELx800, BioTek Instruments Inc., Winooski, VT What's new? Indoleamine 2,3-dioxygenase 1 (IDO) catabolizes tryptophan through the kynurenine (kyn) pathway, whose activity has been correlated with impaired clinical outcome in colorectal cancer (CRC). The function of IDO activity in CRC, however, remains unclear. Here, the authors demonstrated the chemopreventive effects of the canonical IDO inhibitor 1-L-MT on colitisassociated cancer, which were independent of adaptive immunity. IDO inhibition in colon cancer cells suppressed CDC20 transcription, thus inducing mitotic death, which was mediated by decreased Kyn production. The authors thus identified the IDO/ Kyn pathway as a promising preventive target for colorectal cancer, and possibly other malignancies.
Analysis of intracellular Kyn expression by flow cytometry
For intracellular Kyn staining, we used a BD Cytofix/Cytoperm Kit (BD Pharmingen, San Diego, CA) following the manufacturer's instructions. Intracellular Kyn expression was detected with Kyn monoclonal Abs (Santa Cruz, CA) and FITC conjugate-goat anti-mouse IgG (as a secondary antibody; KeyGen Biotech, Nanjing, China). Stained cells were analyzed by a fluorescence-activated cell sorter (AccuriV R C6, Becton Dickinson, Franklin Lakes, NJ).
Measurement of intracellular ROS level
ROS Assay kit purchased from Beyotime Institute of Biotechnology was used according to the manufacturer's instructions. Cells were cultured in a 12-well plate, treated with various stimulations, and then, the cells were harvested and incubated with 100 lM DCFH-DA attenuated with serum-free medium for 20 min at 378C in the dark, washed twice with cold PBS. The fluorescence intensity was measured by fluorescence-activated cell sorter (AccuriV R C6, Becton Dickinson, Franklin Lakes, NJ).
Assay of mitochondrial membrane potential (MMP)
HCT-116 and HT-29 were stimulated with 1-L-MT or INCB for 48 hr. MMP was analyzed by JC-1 staining according to the manufacturer's instructions (MMP assay kit with JC-1, Beyotime Biotechnology, Shanghai, China). The JC-1 dye serves as an indicator of MMP; JC-1 aggregates in mitochondria exhibit red fluorescence, but membrane depolarization prevents aggregation and increases green fluorescence. After incubation, cells were washed once with PBS. The intensity of JC-1 staining was measured by fluorescence microscopy at an excitation wavelength of 505 nm with a 534-nm emission filter (Olympus fluorescent microscope, Japan).
RNA extraction and real-time RT-PCR
Total RNA was isolated using the TRIzol reagent (Invitrogen) according to the manufacturer's protocol. The concentration and purity of the extracted RNA were measured with the optical densities at 260 and 280 nm. RNA samples were reverse transcribed to cDNA and subjected to quantitative PCR, which was performed with the Light-Cycler_96 RealTime PCR System (Roche) using AceQ qPCR SYBR Green Master Mix (Vazyme).
EdU cell proliferation assay
HCT116 and HT-29 cells were seeded in 12-well plates at a density of 2 3 10 5 cells per well. After adhesion, cells were stimulated with 1-L-MT or INCB for 24 hr. Cell proliferation was evaluated by measuring EdU incorporation during DNA synthesis according to the manufacturer's instructions (Baseclick). EdU incorporation was measured using immunofluorescence (Olympus fluorescent microscope, Japan).
Apoptosis analysis
For fluorescence staining assay, the cells were washed with cold PBS, and incubated with Annexin V-FITC and propidium iodide (PI) in turns. After different stimulations, HCT-116 and HT-29 were re-suspended cells were stained with AnnexinV-FITC in dark for 15 min under 48C and subsequently treated by PI for 5 min under the same conditions. The stained cells were subjected to a flow cytometer (AccuriV R C6, Becton Dickinson, Franklin Lakes, NJ) for quantitative analysis. Annexin V1/PI-(early apoptosis) together with Annexin V1/PI1 cells (late apoptosis) were deemed as apoptotic portion.
Cell cycle assay
After treatment with 1-L-MT or INCB for 24 or 48 hr, HCT-116 and HT-29 were harvested, spin down and the resulting pellets were fixed in ice-cold 70% ethanol. Fixed cells were centrifuged, washed and re-suspended in PBS containing RNase A (1 mg/ml), and PI was added (1.0 mg/ml). PIstained cells were analyzed by a fluorescence-activated cell sorter (AccuriV R C6, Becton Dickinson, Franklin Lakes, NJ), followed by the determination of the percentage of cells in G0/G1, S, and G2/M.
Analysis of cell cycle progression and mitotic index
Cell cycle progression was monitored using DNA flow cytometry. DNA was stained with PI, and mitotic cells were quantified by measuring the expression of a mitosis-specific marker, phospho-histone H3 (p-histone H3). In brief, the cells were trypsinized, washed with cold PBS, fixed with icecold 70% ethanol for 16 hr and immunostained with an antip-histone H3 antibody (Cell Signaling Technology) followed by a FITC-conjugated goat anti-rabbit antibody (KeyGEN Biotech). The cells were then stained with 4 lg/ml PI in PBS containing 1% Triton X-100 and 0.1 mg/ml RNase A. pHistone H3 levels and the DNA content of individual cells were analyzed using a fluorescence-activated cell sorting cater-plus flow cytometry (AccuriV R C6, Becton Dickinson, Franklin Lakes, NJ).
Transfection of siRNA
AhR, BubR1, IDO and MAD2 siRNA were synthesized by Sango Biotech, and transformed according to the manufacturer's instruction of Ecfect Transfection reagent (Vazyme). The sequences of siRNA are as following: BubR1 siRNA,
Animal studies and colitis-associated colon cancer
Animal welfare and experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, the United States) and the related ethical regulations of our university. Pathogen-free male C57BL/6 mice and Rag1-/-mice were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China) at 5 weeks of age, IDO knock-out (IDO-/-), on the C57BL/6, were originally purchased from The Jackson Laboratory (Bar Harbor, ME). They were exposed to a 12:12-hr light/dark cycle. At 6 weeks of age, mice received intraperitoneal 10 mg/kg azoxymethane (AOM, Sigma, St. Louis, MO) followed by 7-day cycles of sterile filtered dextran sodium sulfate (DSS, TdB Consultancy, Uppsala, Sweden) at 2.5% in their drinking water. Purified diets were prepared by Xietong-organism Co., LLC (Nanjing Jiangsu, China). Mice were allowed to eat ad libitum. Mice were euthanized at the end of the experiment and colon tissue harvested.
Histopathology
Immunohistochemical stains against IDO, Kyn, CDC20, Ki67 and caspase-3 were performed using immunohistochemistry kit (Key-GEN, Nanjing, China). Briefly, paraffin-embedded slides were deparaffinized, rehydrated and washed in 1% PBS-Tween. Then they were treated with 3% hydrogen peroxide and blocked with 10% goat serum for 1 hr at 378C. Slides were incubated with primary antibodies in PBS containing 1% BSA (1:50) for 1 hr at 378C. Biotinylated secondary anti-rabbit antibodies were added and incubated at room temperature for 1 hr. Streptavidin-HRP was added, and after 40 min the sections were stained with DAB substrate and counterstained with hematoxylin. Histopathology analysis was performed as previously described.
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Immunofluorescence
Immunofluorescence was performed on paraffin-embedded colonic tissue sections (5 ml). The sections were deparaffinized, rehydrated and washed in 1% PBS-Tween. Then they were treated with 3% hydrogen peroxide, blocked with 10% goat serum and incubated with Tunnel for 1 hr at 378C. The slides were stained with DAPI. Images were acquired by confocal laser-scanning microscope (Olympus, Lake Success, NY). Settings for image acquisition were identical for control and experimental tissues.
Statistical analysis
Results are presented as the mean 6 SD. Statistical analyses were performed with the t-test for two groups or one-way ANOVA (GraphPad Software) for multiple groups. . 1c ) and kynurenine acid secretion (Fig. 1c) . Plate clone formation assay further confirmed that IDO inhibition in colon cancer cells indeed suppressed their proliferation (Supporting Information Fig. 1d) . Altogether, these data demonstrated that both 1-L-MT and INCB inhibited colon cancer cell proliferation in vitro.
Long time exposure to IDO inhibitors led to apoptosis of colon cancer cells 
IDO inhibition induced mitotic cell accumulation in colon cancer cells
As shown in Figure 2a , the percentage EdU-positive HCT116 and HT-29 cells were reduced by IDO inhibitors treatment, verifying the proliferative suppression induced by 1-L-MT and INCB. Spindle checkpoint machinery controls the fidelity of chromosome segregation in mitosis and maintains proper mitotic exit and Mad2, CDC20 and BubR1 are vital components of the spindle checkpoint machinery. As shown in Figures 2b-2e IDO inhibitors markedly increased the BubR1 and MAD2 expressions, which peaked at 2 to 8 hr, and then gradually decreased. While, the protein level of CDC20 was suppressed dramatically at 24 hr. In order to determine whether IDO inhibitors-treated cells were arrested at the mitotic phase, HCT-116 and HT-29 cells were stained with p-histone H3 (a mitotic marker) and PI. As seen in Figure  2f , mitotic cells were increased by IDO inhibitors. Figures  2g-2j showed that IDO inhibition-mediated mitotic cell accumulation was not affected by silence of either BubR1 or MAD2, indicating that the effects of 1-L-MT and INCB on mitotic cell accumulation did not involve MAD2 or BubR1.
IDO inhibitors induced mitotic death of colon cancer cells via suppressing CDC20 expression
As shown in Figures 3a and 3b , the degradation of cyclin B1, and following inhibition of CDK, with phosphorylation at Thr161 and dephosphorylation at Tyr15, were suppressed by IDO inhibitors. 1-L-MT and INCB promoted the maintenance of microtubule polymerization with increased microtubule density (Fig. 3c) , which was similar to paclitaxel (a microtubule polymerizing agent). As shown in Figures 3a and 3b , treatment with IDO inhibitors induced a marked decrease soluble in atubulin and a commensurate marked increase in insoluble atubulin, indicating that microtubule polymerization was maintained in colon cancer cells when exposed to IDO inhibitors. To further determine the relationship between mitotic arrest and cell death, immunoblotting was performed for PARP, which is cleaved during apoptosis, and for MPM2, which recognizes mitotic phosphoproteins (Figs. 3d-3g) . PARP cleavage in HCT-116 and HT-29 was coincident with strong MPM2 staining, suggesting that IDO inhibition contributed to mitotic death. BubR1 and MAD2 (Figs. 3h-3i) were not involved in the IDO inhibitor-induced mitotic cell death while CDC20 was required in the regulation of IDO on mitotic death of colon cancer cells (Figs. 3j-3m ). Taken together, these results revealed that CDC20 played a critical role in IDO inhibitors-induced mitotic death of colon cancer cells.
IDO inhibition resulted in mitochondrial damage and caspase-dependent apoptosis
A remarkable ROS accumulation was induced by both 1-L-MT and INCB, detected by DCFH-DA staining (Supporting Information Figs. 2a and 2b) . JC-1 dye was adopted to test MMP. Significant enhancement of green fluorescence, indicating a decrease in MMP, was caused by IDO inhibition (Supporting Information Fig. 2c) . Moreover, Cytochrome C released was increased by treatment of IDO inhibitors in a time-dependent manner, confirming that mitochondrial injuries were caused by IDO suppression (Supporting Information  Figs. 2d-2f) . Accordingly, 1-L-MT and INCB led to the activations of caspases in colon cancer cells, with increased levels of cleaved caspase-3, 28 and 29, and decreased level of BCL-2 expression (Supporting Information Figs. 2g-2j ). To validate a role of CDC20 in IDO inhibitors-mediated apoptosis, CDC20 siRNA was used to intervene CDC20 expression. No remarkable changes of cleaved caspase-3, 28, 29 and BCL-2 were observed in CDC20 siRNA-transfected cells with or without IDO inhibitors treatment (Supporting Information Figs. 2k  and 2l ). In conclusion, IDO inhibitors induced apoptosis of colon cancer cells via suppressing CDC20. Fig. 3b) . Similarly, cell cycle arrest-mediated apoptosis (Supporting Information Figs. 3c and 3d ) and the change of associated proteins (Supporting Information Figs. 3e and 3f ) by 1-L-MT and INCB was compromised by Kyn stimulation. To pinpoint whether IDO regulated colon cancer cell proliferation via Kyn, IDO siRNA was used to suppress endogenous IDO expression (Supporting Information Fig. 3g) , and Kyn stimulation rescued the decreased expression of Ki67 in colon cancer cells (Supporting Information Figs. 3h and 3i) . These results suggested that IDO-mediated Kyn was required for colon cancer cells proliferation.
Kyn rescued IDO inhibition-induced mitotic cell death

AhR was dispensable in Kyn-induced CDC20 transcription
We assessed the effects of Trp, Kyn and INF-g on HCT-116 and HT-29 cell viability using MTT assay. As shown in (Figs. 4b and 4c) , which accelerated the cell cycle and proliferation. Furthermore, both activation of IDO by INF-g and increased level of its metabolite, Kyn, remarkably promoted CDC20 transcription (Fig. 4d) . It is known that aryl hydrocarbon receptor (AhR), a ligand-operated transcription factor, was a major receptor of Kyn. We then explored the potential role of AhR, and found that its protein level could neither be changed by IDO inducer nor inhibitors (Fig. 4e) . Consistently, 1-L-MT and INCB also inhibited CDC20 expression in AhR-silenced HCT-116 and HT-29 cells, confirming that AhR was not required in the regulation of IDO on CDC20 (Figs. 4f and 4g) . Moreover, the nuclear translocation of AhR was not affected by IDO inhibitors (Fig. 4h) . And when AhR activation was inhibited by CH223191, 1-L-MT and INCB still suppressed CDC20 expression, which further validated that AhR was dispensable in this process (Fig. 4i) . Interestingly, we found that Kyn could translocate into nucleus of colon cancer cells (Fig. 4j) . There may be other nuclear transcription factors mediating CDC20 transcription, which should be explored in further. Taken together, Kyn promoted transcription of CDC20 independent of AhR activation.
1-L-MT prevented colitis-associated tumorigenesis
To further test whether the in vitro biological effects of IDO inhibition on colon cancer cells were also true in vivo, an AOM/DSS-induced CAC model was used (Fig. 5a) . Relative body weight of the mice was recorded during the experiment (Fig. 5b) . 1-L-MT decreased weight loss of mice comparing with AOM/DSS group. Based on Kaplan-Meier survival curves, administration of 1-L-MT increased the survival of mice (Fig. 5c) . Average tumor size in 1-L-MT groups was smaller than that of AOM/DSS group (Figs. 5d and 5e ). Consistently, non-polypoid dysplasia was also attenuated with administration of different doses of 1-L-MT (Fig. 5f) . What is more, histology score was reduced by 1-L-MT administration, represented by clinical parameters containing weight loss, stool consistency and bleeding, respectively (Fig. 5g) . Compared with the AOM/DSS group, there was a remarkable increase in colon length of mice in the 1-L-MT groups (Fig.  5h) . Hence, the data strongly revealed that a diet supplemented with 1-L-MT prevented colorectal tumorigenesis in a mouse model of CRC.
1-L-MT suppressed IDO/Kyn pathway in CRC
We next explored the activity of IDO in this CRC model. INF-g (Supporting Information Figs. 4a and 4i) , Trp (Supporting Information Figs. 4b and 4j) and Kyn (Supporting Information Figs. 4c and 4g ) in serum and colon section were measured. It was found that 1-L-MT remarkably inhibited AOM/DSS-induced elevated levels of INF-g and Kyn. Meanwhile, the enhanced ratio of Kyn to Trp was blocked by different doses of 1-L-MT (Supporting Information Figs. 4d  and 4h ). As shown in Supporting Information Figure 4e , the mRNA levels of IDO and CDC20 were notably suppressed by 1-L-MT in tumor, but not in the mucosa of the colon section, which is consistent with their protein expressions (Supporting Information Fig. 4f ). However, INF-g mRNA expressions were similar among all groups. Immunochemistry assay reflected that AOM/DSS-induced expressions of IDO, Kyn and CDC20 were significantly suppressed by 1-L-MT (Supporting Information Fig. 4k ). Apoptosis in tumor tissues in 1-L-MT groups was evaluated shown by TUNEL assay, indicating that apoptosis index of tumor with lower IDO expression was much higher than that of AOM/DSS group (Supporting Information Fig. 4m) . However, comparing with AOM/DSS group, a little decreased expression of Ki67 and increased expression of caspase-3 were observed in 1-L-MT treatment groups. These results suggested that 1-L-MT inhibited IDO activation and induced apoptotic cells in the tumor of colon section. (Figs. 6a and 6b ). There were almost no differences in tumor number and size between IDO-/-group and 1-L-MT group. The mortality in WT group was higher than that in IDO-/-group (Fig. 6c) . Histological analysis exhibited that erosion and distortion of crypts and a non-polypoid dysplasia were also similar in IDO-/-mice with or without 1-L-MT administration (Figs. 6d and 6e) . AOM/DSS induced higher Kyn to Trp ratio, and IDO deficiency abolished this enhancement, while 1-L-MT did not cause any further suppression (Fig. 6f) . In the meantime, we found that the increased protein levels of IDO, CDC20 and Kyn in WT group could hardly be detected by Western blot and Immunohistochemistry in IDO-/-mice (Figs. 6g and 6h) . Comparing with WT group, apoptosis could be detected in tumor of IDO-/-mice, and there was not significant difference observed in IDO-/-mice with or without 1-L-MT treatment (Fig. 6i) . Taken together, these results suggested that 1-L-MT alleviated CRC via inhibiting IDO.
1-L-MT prevented CRC and induced tumor apoptosis independent of its effect on adaptive immunity
To identify the non-immunomodulatory effects of IDO inhibition by 1-L-MT, we established CRC model in Rag1-/-mice, which were absent of T cells. As expected, administration of 1-L-MT (200 mg/kg) reduced tumor number and size, which was induced by AOM/DSS (Supporting Information Figs. 5a and 5b ). 1-L-MT also rescued the decreased survival rate of Rag1-/-mice induced by AOM/DSS (Supporting Information Fig. 5c ). HE staining and histology score further confirmed the effects of 1-L-MT on CRC (Supporting Information Figs. 5d and 5e ). As shown in Supporting Information Figures 5f and 5g, IDO activation and CDC20 expression were obviously decreased by 1-L-MT. More apoptotic tumor cells in the colon section were detected in 1-L-MT group than in AOM/DSS group (Supporting Information Fig. 5h ). These results indicated the chemopreventive effect of 1-L-MT in colitis-associated colorectal cancer did not involve its regulatory effect on adaptive immunity.
Discussion
IDO regulates the rate-limiting step of the Kyn pathway of Trp metabolism. 23 Research has been focused on IDOmediated immune tolerance. It was found that IDO-expressing tumor cells regulated the immune escape of themselves. 24 We found that there were more Tregs and fewer CD8
1 T cells infiltrated in the colon section of AOM/DSS group, comparing with control group (data not shown). IDO-/-mice harbored fewer tumors, with significantly increased CD8 1 T cells and decreased Tregs infiltration. Indeed, IDOmediated immune tolerance contributed to tumor progression in CRC. Interestingly, 1-L-MT also prevented CRC in Rag1-/-mice, which lack T cells. That is, IDO inhibition could suppress cancer development independent of its regulatory effects on adaptive immunity. Besides immune regulation, IDO activation affected tumor cell viability, proliferation and apoptosis in vitro. Consistently, previous study reported that Kynurenine and quinolinic acid (QA), but not picolinic acid, rescued cell proliferation in the IDO blockade in colon cancer cell lines, including HCT-116 cells. 15 We speculated that IDO activation in tumors may have two complementary functions: to mediate tumoral immune tolerance and to accelerate tumor cell proliferation. 25, 26 The severity of colitis contributes to the development of CRC. The effects of IDO have been investigated in many kinds of colitis models. In TNBS-induced colitis, which is modulated by T cells, IDO, a natural brake, regulated the transdifferentiation of Th1 and Th17 during inflammation. 27, 28 However, the activity of IDO was reported to be dispensable in DSS-induced colitis model. IDO-/-mice showed similar spontaneous intestinal inflammation as that in WT Group. 29 While, Matteoli et al. pinpointed that IDO inhibitor worsened the severity of colitis in the recovery phase of epithelial reconstitution after severe injury with 5% DSS. 28 Together with the current study, these data verified that IDO inhibitors prevented CRC independent of adaptive immunity. 1 T cells, and proliferation of Tregs. 30 Moreover, GCN2 could be activated by asparagine or glucose starvation in tumor microenvironment, which was involved in the regulation of immune tolerance. 31 However, our in vivo study reflected that the concentration of tryptophan was similar among control, AOM/DSS and 1-L-MT administration groups. The stimulation of Trp did not influence the viability of colon cancer cells. What is more, IDO-induced Trp starvation did not exhibit any regulatory effects of T cells function, and additional Trp not only could not rescue IDO-mediated T cell inhibition, but also failed to affect colon cancer cell proliferation (data not shown). In summary, tumor-based IDO activation drove progression of CRC independent of essential amino acid starvation.
In the present study, Kyn, a metabolite of Trp, played an essential role in the effects of IDO on colon cancer cells. We found that Kyn increased CDC20 transcription. IDO inhibition blocked this enhancement, and induced cell cycle arrestmediated apoptosis. Cell cycle checkpoints are critical in the regulation of DNA repair, apoptosis and differentiation.
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CDC20 is essential in metaphase-to-anaphase transition. Under circumstances of chromosome misalignment, CDC20 can be suppressed by other proteins, including MAD2, resulting in delayed anaphase. While, after correcting chromosomal alignment, CDC20 is activated, and then trigger polyubiquitination and proteasomal degradation of securin and cyclin B. 33 After stimulation of IDO inhibitors, both mRNA and protein levels of CDC20 were decreased. Meanwhile, colon cancer cells, including HCT-116 and HT-29 underwent G2/ M cycle arrest, but no obvious apoptosis was detected. After incubation for 48 hr, both cell cycle arrest and apoptosis were observed. In order to determine whether IDO induced apoptosis via cell cycle arrest, cell cycle and apoptosis-related proteins were examined. PARP cleavage, a marker of apoptosis, was coincidently increased with strong MPM2 staining, a key protein in cell cycle, demonstrating that IDO inhibition mediated colon cancer cells death in mitosis. Additionally, 1-L-MT and INCB could not induce more apoptosis in CDC20 siRNA-transfected colon cancer cells. These data verified that CDC20, a regulator of cell cycle, mediated cell cycle disaster 34 of colon cancer cells.
Kyn promoted transcription of CDC20 in our study. While AhR, a major receptor of Kyn, was not required in CDC20 transcription. When AhR was knockdown or inhibited, 1-L-MT and INCB still inhibited the proliferation of colon cancer cells. Previous study provided evidence that IDO/Kyn/IL-6 axis modulated cell proliferation. PTEN, for example, was a negative regulator of mitotic checkpoint complex during cell cycle via interacting with CDC20 and MAD2. 35 Cytochrome P450 1B1 expression was reported to be associated with CDC20 expression in clinical samples of renal cell carcinoma, 36 which had an impact on IDO/Kyn/ AhR pathway. It is still unknown whether there is a crosslink between the IDO pathway and CDC20-associated mitotic arrest. Further in-depth biochemical analysis about the interaction between IDO/Kyn and CDC20-related apoptosis should provide mechanistic insights.
It was reported that kynurenine levels did not always correlate with IDO1 expression, 37 and NAD1 synthesis was not impaired by 1-L-MT In murine tumor models. 38 The expression of Trp 2,3-dioxygenase (TDO) may take part in the progression of CRC. 39 While, in our study, we found that IDO-/-mice showed lower Kyn level (Supporting Information Fig. 5g ) and administration of Kyn could reverse the effects of IDO deficiency (data not shown). What is more, Ogawa et al. demonstrated that TDO exerted little effect on L-kynurenine levels, because the expression of TDO was similar between the AOM-treated group and the control group. 21 In our study, we found that 1-L-MT exerted chemopreventive effects mainly dependent on decreased Kyn. We could not exclude the role of TDO, but the specific role of it would need to be explored in further experiments.
It is known that CRC is one of the most commonly diagnosed cancer. Many preventative measures, including dietary and lifestyle modifications, are considered as attractive strategies to reduce the global burden of CRC. Owing to availability and safety, dietary supplements could be a better choice to prevent CRC. IDO upregulation contributed to the early phase of colon carcinogenesis, and 1-MT could potentially be used for chemoprevention of CRC. 1-MT has two racemic isoforms, 1-L-MT and 1-D-MT. 1-L-MT is the classic noncompetitive inhibitor of IDO1, and 1-D-MT has been suggested to be less active in inhibiting IDO1, 40 but showing higher potency in target IDO2, 41 whose physiological relevance particularly in humans remains unclear. 1-L-MT was reported to be more effective in abrogating kynurenine generation and tryptophan depletion, thus reversing IDO-induced arrest of human T-cell proliferation. 42 The tissue distributions of 1-L-MT and 1-D-MT are different, with 1-L-MT distributed mainly in pancreas and 1-D-MT in kidney, respectively. 43 Even though 1-D-MT was used to treat several types of cancers in combination with other chemotherapy drugs, the mechanism of it is still unclear, and there were cell type-specific differences between 1-L-MT and 1-D-MT. 44 Previous study demonstrated that the effect of 1-L-MT was >1-D-MT on anti-proliferation of colon cancer cells. 15 What is more, 1-D-MT was also reported to upregulate IDO in cancer cells. 45 In our study, we found IDO1-/-mice harbored fewer tumors in colon section, comparing with WT mice. Thus, we chose 1-L-MT as a chemopreventive agent for colorectal cancer in our present study. What is more, 200 mg/kg and 400 mg/kg 1-L-MT in mice, equivalent to 21.9 and 43.95 mg/kg in humans, are lower than 30 mg/kg body wt twice daily for a 70 kg adult clinically used for 1-D-MT. 46 The exact doses of 1-L-MT to be tolerable and effective in human would require further clinical investigations.
Our results showed that IDO activation played a critical role in CRC progression, which provided mechanistic evidence for the phenomena that high IDO expression was associated with poor prognosis of human CRC. Our investigation provided new insight into the chemopreventive effects of 1-L-MT, an IDO inhibitor, on CRC. IDO inhibition suppressed tumor growth and induced apoptosis in tumor cells via reducing CDC20 transcription and inducing mitochondrial injuries. These results exhibited important implications for IDO inhibitors as chemopreventive agents for IDOexpressing colitis-associated and sporadic colonic neoplasms. What is more, regulation of the Kyn pathway in the colon section could be regarded as a chemopreventive target for CRC and other malignancies.
